Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
13,253
archived clinical trials in
Arthritis

A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated:  11/3/2017
Clinical Research Facility
mi
from
Kalamazoo, MI
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated: 11/3/2017
Clinical Research Facility
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated:  11/3/2017
Clinical Research Facility
mi
from
Lansing, MI
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated: 11/3/2017
Clinical Research Facility
mi
from
Lansing, MI
Click here to add this to my saved trials
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated:  11/3/2017
Clinical Research Facility
mi
from
Columbia, MO
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated: 11/3/2017
Clinical Research Facility
mi
from
Columbia, MO
Click here to add this to my saved trials
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated:  11/3/2017
Clinical Research Facility
mi
from
Las Vegas, NV
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated: 11/3/2017
Clinical Research Facility
mi
from
Las Vegas, NV
Click here to add this to my saved trials
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated:  11/3/2017
Clinical Research Facility
mi
from
Freehold, NJ
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated: 11/3/2017
Clinical Research Facility
mi
from
Freehold, NJ
Click here to add this to my saved trials
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated:  11/3/2017
Clinical Research Facility
mi
from
Toms River, NJ
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated: 11/3/2017
Clinical Research Facility
mi
from
Toms River, NJ
Click here to add this to my saved trials
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated:  11/3/2017
Clinical Research Facility
mi
from
Albany, NY
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated: 11/3/2017
Clinical Research Facility
mi
from
Albany, NY
Click here to add this to my saved trials
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated:  11/3/2017
Clinical Research Facility
mi
from
Hartsdale, NY
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated: 11/3/2017
Clinical Research Facility
mi
from
Hartsdale, NY
Click here to add this to my saved trials
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated:  11/3/2017
Clinical Research Facility
mi
from
Asheville, NC
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated: 11/3/2017
Clinical Research Facility
mi
from
Asheville, NC
Click here to add this to my saved trials
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated:  11/3/2017
Clinical Research Facility
mi
from
Charlotte, NC
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated: 11/3/2017
Clinical Research Facility
mi
from
Charlotte, NC
Click here to add this to my saved trials
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated:  11/3/2017
Clinical Research Facility
mi
from
Middleburg Heights, OH
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated: 11/3/2017
Clinical Research Facility
mi
from
Middleburg Heights, OH
Click here to add this to my saved trials
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated:  11/3/2017
Clinical Research Facility
mi
from
Tulsa, OK
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated: 11/3/2017
Clinical Research Facility
mi
from
Tulsa, OK
Click here to add this to my saved trials
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated:  11/3/2017
Clinical Research Facility
mi
from
Portland, OR
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated: 11/3/2017
Clinical Research Facility
mi
from
Portland, OR
Click here to add this to my saved trials
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated:  11/3/2017
Clinical Research Facility
mi
from
Bethlehem, PA
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated: 11/3/2017
Clinical Research Facility
mi
from
Bethlehem, PA
Click here to add this to my saved trials
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated:  11/3/2017
Clinical Research Facility
mi
from
Wyomissing, PA
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated: 11/3/2017
Clinical Research Facility
mi
from
Wyomissing, PA
Click here to add this to my saved trials
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated:  11/3/2017
Clinical Research Facility
mi
from
Myrtle Beach, SC
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated: 11/3/2017
Clinical Research Facility
mi
from
Myrtle Beach, SC
Click here to add this to my saved trials
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated:  11/3/2017
Clinical Research Facility
mi
from
Cypress, TX
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated: 11/3/2017
Clinical Research Facility
mi
from
Cypress, TX
Click here to add this to my saved trials
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated:  11/3/2017
Clinical Research Facility
mi
from
Dallas, TX
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated: 11/3/2017
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated:  11/3/2017
Clinical Research Facility
mi
from
Lubbock, TX
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated: 11/3/2017
Clinical Research Facility
mi
from
Lubbock, TX
Click here to add this to my saved trials
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated:  11/3/2017
Clinical Research Facility
mi
from
Nassau Bay, TX
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated: 11/3/2017
Clinical Research Facility
mi
from
Nassau Bay, TX
Click here to add this to my saved trials
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated:  11/3/2017
Clinical Research Facility
mi
from
Webster, TX
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated: 11/3/2017
Clinical Research Facility
mi
from
Webster, TX
Click here to add this to my saved trials
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated:  11/3/2017
Clinical Research Facility
mi
from
Chesapeake, VA
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated: 11/3/2017
Clinical Research Facility
mi
from
Chesapeake, VA
Click here to add this to my saved trials
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated:  11/3/2017
Clinical Research Facility
mi
from
Kennewick, WA
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated: 11/3/2017
Clinical Research Facility
mi
from
Kennewick, WA
Click here to add this to my saved trials
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated:  11/3/2017
Clinical Research Facility
mi
from
Vancouver, WA
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated: 11/3/2017
Clinical Research Facility
mi
from
Vancouver, WA
Click here to add this to my saved trials
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated:  11/3/2017
Clinical Research Facility
mi
from
Franklin, WI
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated: 11/3/2017
Clinical Research Facility
mi
from
Franklin, WI
Click here to add this to my saved trials
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated:  11/3/2017
Clinical Research Facility
mi
from
Saint Louis, MO
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated: 11/3/2017
Clinical Research Facility
mi
from
Saint Louis, MO
Click here to add this to my saved trials
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated:  11/3/2017
mi
from
Buenos Aires,
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis
Status: Enrolling
Updated: 11/3/2017
mi
from
Buenos Aires,
Click here to add this to my saved trials
Comparative Effectiveness of an Activity-specific Monitoring Device- StepRite
Comparative Effectiveness of an Activity-specific Monitoring Device- StepRite - on Short Term Outcomes in Adults After Partial or Total Knee Arthroplasty
Status: Enrolling
Updated:  11/6/2017
TTUHSC Orthopaedic Surgery MS 9436
mi
from
Lubbock, TX
Comparative Effectiveness of an Activity-specific Monitoring Device- StepRite
Comparative Effectiveness of an Activity-specific Monitoring Device- StepRite - on Short Term Outcomes in Adults After Partial or Total Knee Arthroplasty
Status: Enrolling
Updated: 11/6/2017
TTUHSC Orthopaedic Surgery MS 9436
mi
from
Lubbock, TX
Click here to add this to my saved trials
Does Physical Therapy Prevent Total Knee Arthroplasty in Patients With End Stage Osteoarthritis
Does Physical Therapy Prevent Total Knee Arthroplasty in Patients With End Stage Osteoarthritis
Status: Enrolling
Updated:  11/10/2017
UNC Orthopaedics
mi
from
Chapel Hill, NC
Does Physical Therapy Prevent Total Knee Arthroplasty in Patients With End Stage Osteoarthritis
Does Physical Therapy Prevent Total Knee Arthroplasty in Patients With End Stage Osteoarthritis
Status: Enrolling
Updated: 11/10/2017
UNC Orthopaedics
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Long-Term Safety and Tolerability of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients
A 36-week Open-label Extension Study of CACZ885H2361 on the Safety and Tolerability of Canakinumab 150 mg s.c. Pre-filled Syringe (PFS) in Treating Acute Gouty Arthritis Flares in Frequently Flaring Patients
Status: Enrolling
Updated:  11/13/2017
Novartis Investigative Site
mi
from
Anniston, AL
Long-Term Safety and Tolerability of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients
A 36-week Open-label Extension Study of CACZ885H2361 on the Safety and Tolerability of Canakinumab 150 mg s.c. Pre-filled Syringe (PFS) in Treating Acute Gouty Arthritis Flares in Frequently Flaring Patients
Status: Enrolling
Updated: 11/13/2017
Novartis Investigative Site
mi
from
Anniston, AL
Click here to add this to my saved trials
Long-Term Safety and Tolerability of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients
A 36-week Open-label Extension Study of CACZ885H2361 on the Safety and Tolerability of Canakinumab 150 mg s.c. Pre-filled Syringe (PFS) in Treating Acute Gouty Arthritis Flares in Frequently Flaring Patients
Status: Enrolling
Updated:  11/13/2017
Novartis Investigative Site
mi
from
Gulf Shores, AL
Long-Term Safety and Tolerability of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients
A 36-week Open-label Extension Study of CACZ885H2361 on the Safety and Tolerability of Canakinumab 150 mg s.c. Pre-filled Syringe (PFS) in Treating Acute Gouty Arthritis Flares in Frequently Flaring Patients
Status: Enrolling
Updated: 11/13/2017
Novartis Investigative Site
mi
from
Gulf Shores, AL
Click here to add this to my saved trials
Long-Term Safety and Tolerability of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients
A 36-week Open-label Extension Study of CACZ885H2361 on the Safety and Tolerability of Canakinumab 150 mg s.c. Pre-filled Syringe (PFS) in Treating Acute Gouty Arthritis Flares in Frequently Flaring Patients
Status: Enrolling
Updated:  11/13/2017
Novartis Investigative Site
mi
from
Mobile, AL
Long-Term Safety and Tolerability of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients
A 36-week Open-label Extension Study of CACZ885H2361 on the Safety and Tolerability of Canakinumab 150 mg s.c. Pre-filled Syringe (PFS) in Treating Acute Gouty Arthritis Flares in Frequently Flaring Patients
Status: Enrolling
Updated: 11/13/2017
Novartis Investigative Site
mi
from
Mobile, AL
Click here to add this to my saved trials
Long-Term Safety and Tolerability of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients
A 36-week Open-label Extension Study of CACZ885H2361 on the Safety and Tolerability of Canakinumab 150 mg s.c. Pre-filled Syringe (PFS) in Treating Acute Gouty Arthritis Flares in Frequently Flaring Patients
Status: Enrolling
Updated:  11/13/2017
Novartis Investigative Site
mi
from
Chandler, AZ
Long-Term Safety and Tolerability of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients
A 36-week Open-label Extension Study of CACZ885H2361 on the Safety and Tolerability of Canakinumab 150 mg s.c. Pre-filled Syringe (PFS) in Treating Acute Gouty Arthritis Flares in Frequently Flaring Patients
Status: Enrolling
Updated: 11/13/2017
Novartis Investigative Site
mi
from
Chandler, AZ
Click here to add this to my saved trials
Long-Term Safety and Tolerability of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients
A 36-week Open-label Extension Study of CACZ885H2361 on the Safety and Tolerability of Canakinumab 150 mg s.c. Pre-filled Syringe (PFS) in Treating Acute Gouty Arthritis Flares in Frequently Flaring Patients
Status: Enrolling
Updated:  11/13/2017
Novartis Investigative Site
mi
from
Scottsdale, AZ
Long-Term Safety and Tolerability of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients
A 36-week Open-label Extension Study of CACZ885H2361 on the Safety and Tolerability of Canakinumab 150 mg s.c. Pre-filled Syringe (PFS) in Treating Acute Gouty Arthritis Flares in Frequently Flaring Patients
Status: Enrolling
Updated: 11/13/2017
Novartis Investigative Site
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Long-Term Safety and Tolerability of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients
A 36-week Open-label Extension Study of CACZ885H2361 on the Safety and Tolerability of Canakinumab 150 mg s.c. Pre-filled Syringe (PFS) in Treating Acute Gouty Arthritis Flares in Frequently Flaring Patients
Status: Enrolling
Updated:  11/13/2017
Novartis Investigator Site
mi
from
Buena Park, CA
Long-Term Safety and Tolerability of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients
A 36-week Open-label Extension Study of CACZ885H2361 on the Safety and Tolerability of Canakinumab 150 mg s.c. Pre-filled Syringe (PFS) in Treating Acute Gouty Arthritis Flares in Frequently Flaring Patients
Status: Enrolling
Updated: 11/13/2017
Novartis Investigator Site
mi
from
Buena Park, CA
Click here to add this to my saved trials
Long-Term Safety and Tolerability of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients
A 36-week Open-label Extension Study of CACZ885H2361 on the Safety and Tolerability of Canakinumab 150 mg s.c. Pre-filled Syringe (PFS) in Treating Acute Gouty Arthritis Flares in Frequently Flaring Patients
Status: Enrolling
Updated:  11/13/2017
Novartis Investigative Site
mi
from
Norwalk, CA
Long-Term Safety and Tolerability of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients
A 36-week Open-label Extension Study of CACZ885H2361 on the Safety and Tolerability of Canakinumab 150 mg s.c. Pre-filled Syringe (PFS) in Treating Acute Gouty Arthritis Flares in Frequently Flaring Patients
Status: Enrolling
Updated: 11/13/2017
Novartis Investigative Site
mi
from
Norwalk, CA
Click here to add this to my saved trials
Long-Term Safety and Tolerability of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients
A 36-week Open-label Extension Study of CACZ885H2361 on the Safety and Tolerability of Canakinumab 150 mg s.c. Pre-filled Syringe (PFS) in Treating Acute Gouty Arthritis Flares in Frequently Flaring Patients
Status: Enrolling
Updated:  11/13/2017
Novartis Investigative Site
mi
from
Westlake Village, CA
Long-Term Safety and Tolerability of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients
A 36-week Open-label Extension Study of CACZ885H2361 on the Safety and Tolerability of Canakinumab 150 mg s.c. Pre-filled Syringe (PFS) in Treating Acute Gouty Arthritis Flares in Frequently Flaring Patients
Status: Enrolling
Updated: 11/13/2017
Novartis Investigative Site
mi
from
Westlake Village, CA
Click here to add this to my saved trials
Long-Term Safety and Tolerability of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients
A 36-week Open-label Extension Study of CACZ885H2361 on the Safety and Tolerability of Canakinumab 150 mg s.c. Pre-filled Syringe (PFS) in Treating Acute Gouty Arthritis Flares in Frequently Flaring Patients
Status: Enrolling
Updated:  11/13/2017
Novartis Investigative Site
mi
from
Jupiter, FL
Long-Term Safety and Tolerability of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients
A 36-week Open-label Extension Study of CACZ885H2361 on the Safety and Tolerability of Canakinumab 150 mg s.c. Pre-filled Syringe (PFS) in Treating Acute Gouty Arthritis Flares in Frequently Flaring Patients
Status: Enrolling
Updated: 11/13/2017
Novartis Investigative Site
mi
from
Jupiter, FL
Click here to add this to my saved trials
Long-Term Safety and Tolerability of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients
A 36-week Open-label Extension Study of CACZ885H2361 on the Safety and Tolerability of Canakinumab 150 mg s.c. Pre-filled Syringe (PFS) in Treating Acute Gouty Arthritis Flares in Frequently Flaring Patients
Status: Enrolling
Updated:  11/13/2017
Novartis Investigative Site
mi
from
Largo, FL
Long-Term Safety and Tolerability of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients
A 36-week Open-label Extension Study of CACZ885H2361 on the Safety and Tolerability of Canakinumab 150 mg s.c. Pre-filled Syringe (PFS) in Treating Acute Gouty Arthritis Flares in Frequently Flaring Patients
Status: Enrolling
Updated: 11/13/2017
Novartis Investigative Site
mi
from
Largo, FL
Click here to add this to my saved trials
Long-Term Safety and Tolerability of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients
A 36-week Open-label Extension Study of CACZ885H2361 on the Safety and Tolerability of Canakinumab 150 mg s.c. Pre-filled Syringe (PFS) in Treating Acute Gouty Arthritis Flares in Frequently Flaring Patients
Status: Enrolling
Updated:  11/13/2017
Novartis Investigative Site
mi
from
South Miami, FL
Long-Term Safety and Tolerability of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients
A 36-week Open-label Extension Study of CACZ885H2361 on the Safety and Tolerability of Canakinumab 150 mg s.c. Pre-filled Syringe (PFS) in Treating Acute Gouty Arthritis Flares in Frequently Flaring Patients
Status: Enrolling
Updated: 11/13/2017
Novartis Investigative Site
mi
from
South Miami, FL
Click here to add this to my saved trials
Long-Term Safety and Tolerability of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients
A 36-week Open-label Extension Study of CACZ885H2361 on the Safety and Tolerability of Canakinumab 150 mg s.c. Pre-filled Syringe (PFS) in Treating Acute Gouty Arthritis Flares in Frequently Flaring Patients
Status: Enrolling
Updated:  11/13/2017
Novartis Investigative Site
mi
from
Augusta, GA
Long-Term Safety and Tolerability of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients
A 36-week Open-label Extension Study of CACZ885H2361 on the Safety and Tolerability of Canakinumab 150 mg s.c. Pre-filled Syringe (PFS) in Treating Acute Gouty Arthritis Flares in Frequently Flaring Patients
Status: Enrolling
Updated: 11/13/2017
Novartis Investigative Site
mi
from
Augusta, GA
Click here to add this to my saved trials
Long-Term Safety and Tolerability of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients
A 36-week Open-label Extension Study of CACZ885H2361 on the Safety and Tolerability of Canakinumab 150 mg s.c. Pre-filled Syringe (PFS) in Treating Acute Gouty Arthritis Flares in Frequently Flaring Patients
Status: Enrolling
Updated:  11/13/2017
Novartis Investigative Site
mi
from
Decatur, GA
Long-Term Safety and Tolerability of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients
A 36-week Open-label Extension Study of CACZ885H2361 on the Safety and Tolerability of Canakinumab 150 mg s.c. Pre-filled Syringe (PFS) in Treating Acute Gouty Arthritis Flares in Frequently Flaring Patients
Status: Enrolling
Updated: 11/13/2017
Novartis Investigative Site
mi
from
Decatur, GA
Click here to add this to my saved trials
Long-Term Safety and Tolerability of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients
A 36-week Open-label Extension Study of CACZ885H2361 on the Safety and Tolerability of Canakinumab 150 mg s.c. Pre-filled Syringe (PFS) in Treating Acute Gouty Arthritis Flares in Frequently Flaring Patients
Status: Enrolling
Updated:  11/13/2017
Novartis Investigator Site
mi
from
Topeka, KA
Long-Term Safety and Tolerability of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients
A 36-week Open-label Extension Study of CACZ885H2361 on the Safety and Tolerability of Canakinumab 150 mg s.c. Pre-filled Syringe (PFS) in Treating Acute Gouty Arthritis Flares in Frequently Flaring Patients
Status: Enrolling
Updated: 11/13/2017
Novartis Investigator Site
mi
from
Topeka, KA
Click here to add this to my saved trials
Long-Term Safety and Tolerability of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients
A 36-week Open-label Extension Study of CACZ885H2361 on the Safety and Tolerability of Canakinumab 150 mg s.c. Pre-filled Syringe (PFS) in Treating Acute Gouty Arthritis Flares in Frequently Flaring Patients
Status: Enrolling
Updated:  11/13/2017
Novartis Investigative Site
mi
from
Louisville, KY
Long-Term Safety and Tolerability of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients
A 36-week Open-label Extension Study of CACZ885H2361 on the Safety and Tolerability of Canakinumab 150 mg s.c. Pre-filled Syringe (PFS) in Treating Acute Gouty Arthritis Flares in Frequently Flaring Patients
Status: Enrolling
Updated: 11/13/2017
Novartis Investigative Site
mi
from
Louisville, KY
Click here to add this to my saved trials
Long-Term Safety and Tolerability of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients
A 36-week Open-label Extension Study of CACZ885H2361 on the Safety and Tolerability of Canakinumab 150 mg s.c. Pre-filled Syringe (PFS) in Treating Acute Gouty Arthritis Flares in Frequently Flaring Patients
Status: Enrolling
Updated:  11/13/2017
Novartis Investigator Site
mi
from
Owensboro, KY
Long-Term Safety and Tolerability of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients
A 36-week Open-label Extension Study of CACZ885H2361 on the Safety and Tolerability of Canakinumab 150 mg s.c. Pre-filled Syringe (PFS) in Treating Acute Gouty Arthritis Flares in Frequently Flaring Patients
Status: Enrolling
Updated: 11/13/2017
Novartis Investigator Site
mi
from
Owensboro, KY
Click here to add this to my saved trials
Long-Term Safety and Tolerability of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients
A 36-week Open-label Extension Study of CACZ885H2361 on the Safety and Tolerability of Canakinumab 150 mg s.c. Pre-filled Syringe (PFS) in Treating Acute Gouty Arthritis Flares in Frequently Flaring Patients
Status: Enrolling
Updated:  11/13/2017
Novartis Investigative Site
mi
from
Metairie, LA
Long-Term Safety and Tolerability of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients
A 36-week Open-label Extension Study of CACZ885H2361 on the Safety and Tolerability of Canakinumab 150 mg s.c. Pre-filled Syringe (PFS) in Treating Acute Gouty Arthritis Flares in Frequently Flaring Patients
Status: Enrolling
Updated: 11/13/2017
Novartis Investigative Site
mi
from
Metairie, LA
Click here to add this to my saved trials
Long-Term Safety and Tolerability of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients
A 36-week Open-label Extension Study of CACZ885H2361 on the Safety and Tolerability of Canakinumab 150 mg s.c. Pre-filled Syringe (PFS) in Treating Acute Gouty Arthritis Flares in Frequently Flaring Patients
Status: Enrolling
Updated:  11/13/2017
Novartis Investigative Site
mi
from
Troy, MI
Long-Term Safety and Tolerability of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients
A 36-week Open-label Extension Study of CACZ885H2361 on the Safety and Tolerability of Canakinumab 150 mg s.c. Pre-filled Syringe (PFS) in Treating Acute Gouty Arthritis Flares in Frequently Flaring Patients
Status: Enrolling
Updated: 11/13/2017
Novartis Investigative Site
mi
from
Troy, MI
Click here to add this to my saved trials
Long-Term Safety and Tolerability of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients
A 36-week Open-label Extension Study of CACZ885H2361 on the Safety and Tolerability of Canakinumab 150 mg s.c. Pre-filled Syringe (PFS) in Treating Acute Gouty Arthritis Flares in Frequently Flaring Patients
Status: Enrolling
Updated:  11/13/2017
Novartis Investigative Site
mi
from
Belzoni, MS
Long-Term Safety and Tolerability of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients
A 36-week Open-label Extension Study of CACZ885H2361 on the Safety and Tolerability of Canakinumab 150 mg s.c. Pre-filled Syringe (PFS) in Treating Acute Gouty Arthritis Flares in Frequently Flaring Patients
Status: Enrolling
Updated: 11/13/2017
Novartis Investigative Site
mi
from
Belzoni, MS
Click here to add this to my saved trials
Long-Term Safety and Tolerability of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients
A 36-week Open-label Extension Study of CACZ885H2361 on the Safety and Tolerability of Canakinumab 150 mg s.c. Pre-filled Syringe (PFS) in Treating Acute Gouty Arthritis Flares in Frequently Flaring Patients
Status: Enrolling
Updated:  11/13/2017
Novartis Investigative Site
mi
from
Jackson, MS
Long-Term Safety and Tolerability of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients
A 36-week Open-label Extension Study of CACZ885H2361 on the Safety and Tolerability of Canakinumab 150 mg s.c. Pre-filled Syringe (PFS) in Treating Acute Gouty Arthritis Flares in Frequently Flaring Patients
Status: Enrolling
Updated: 11/13/2017
Novartis Investigative Site
mi
from
Jackson, MS
Click here to add this to my saved trials
Long-Term Safety and Tolerability of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients
A 36-week Open-label Extension Study of CACZ885H2361 on the Safety and Tolerability of Canakinumab 150 mg s.c. Pre-filled Syringe (PFS) in Treating Acute Gouty Arthritis Flares in Frequently Flaring Patients
Status: Enrolling
Updated:  11/13/2017
Novartis Investigative Site
mi
from
Picayune, MS
Long-Term Safety and Tolerability of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients
A 36-week Open-label Extension Study of CACZ885H2361 on the Safety and Tolerability of Canakinumab 150 mg s.c. Pre-filled Syringe (PFS) in Treating Acute Gouty Arthritis Flares in Frequently Flaring Patients
Status: Enrolling
Updated: 11/13/2017
Novartis Investigative Site
mi
from
Picayune, MS
Click here to add this to my saved trials